

# Jos L Ferreiro

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7756782/jose-l-ferreiro-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82 papers	2,262 citations	25 h-index	45 g-index
92 ext. papers	2,587 ext. citations	3.9 avg, IF	4.92 L-index

#	Paper	IF	Citations
82	Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3008	5.1	0
81	Impact of sex differences and network systems on the in-hospital mortality of patients with ST-segment elevation acute myocardial infarction. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2021</b> , 74, 927-934	0.7	3
80	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , <b>2021</b> , 42, 2973-2985	9.5	10
79	Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2021</b> , 74, 1013-1022	0.7	1
78	Antithrombotic strategies in elderly patients with atrial fibrillation revascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 338, 63-71	3.2	1
77	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2020</b> , 73, 749-757	0.7	11
76	Antithrombotic Therapy After Transcatheter Aortic Valve Implantation. <i>European Cardiology Review</i> , <b>2020</b> , 15, 1-8	3.9	6
75	Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial. <i>EuroIntervention</i> , <b>2020</b> , 16, e155-e163	3.1	7
74	Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease. <i>Thrombosis Research</i> , <b>2020</b> , 196, 215-221	8.2	
73	High and low on-treatment platelet reactivity to P2Y inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , <b>2019</b> , 175, 95-101	8.2	7
72	Ticagrelor in patients with myocardial infarction: is the treatment strategy crystal clear?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 207-209	6.4	1
71	In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 917-925	0.7	3
70	Comentarios a la actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria. <i>Revista Espanola De Cardiologia</i> , <b>2018</b> , 71, 6-12	1.5	
69	Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 6-12	0.7	1
68	Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration. <i>Journal of Cardiology</i> , <b>2018</b> , 72, 94-104	3	11
67	IVUS Findings in Late and Very Late Stent Thrombosis. A Comparison Between Bare-metal and Drug-eluting Stents. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 335-343	0.7	3
66	Antithrombotic Therapy and Surgery: From Consensus to Clinical Practice. Response to Related Letters. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 879	0.7	

65	Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 553-564	0.7	12
64	Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. <i>International Journal of COPD</i> , <b>2018</b> , 13, 141-148	3	8
63	Temporal trends in frequency, management and outcomes of coronary perforations. <i>Minerva Cardiology and Angiology</i> , <b>2018</b> , 66, 361-367	2.4	
62	Long-term prognostic impact of non-invasive follow-up with computed tomography angiography in patients with left main coronary artery stenting. <i>Minerva Cardioangiologica</i> , <b>2018</b> , 66, 528-535	1.1	2
61	Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1559-1571	5	22
60	One-year optical coherence tomography findings in patients with late and very-late stent thrombosis treated with intravascular imaging guided percutaneous coronary intervention. <i>International Journal of Cardiovascular Imaging</i> , <b>2018</b> , 34, 1511-1520	2.5	4
59	Noninvasive Follow-Up of Patients With Spontaneous Coronary Artery Dissection With CT Angiography. <i>JACC: Cardiovascular Imaging</i> , <b>2016</b> , 9, 896-897	8.4	61
58	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 42-50	5	55
57	Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. <i>Platelets</i> , <b>2016</b> , 27, 777-783	3.6	3
56	Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor. <i>Current Atherosclerosis Reports</i> , <b>2016</b> , 18, 66	6	6
55	Body mass index and acute coronary syndromes: paradox or confusion?. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 158-64	4.3	3
54	Predictive ability of bleeding risk scores in the routine clinical practice. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 205-10	4.3	7
53	Preserved endothelial vasomotor function after everolimus-eluting stent implantation. <i>EuroIntervention</i> , <b>2015</b> , 11, 643-9	3.1	13
52	Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. <i>Journal of Cardiovascular Translational Research</i> , <b>2014</b> , 7, 39-46	3.3	16
51	Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 426-34	5	25
50	Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1005-14	15.1	121
49	Prediction of bleeding in patients with acute coronary syndromes: applying the new BARC definition. <i>Thrombosis Research</i> , <b>2014</b> , 133, 952-4	8.2	1
48	Time since diabetes onset as a determining factor in platelet reactivity. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2014</b> , 67, 243	0.7	

47	Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 258-65	7	11
46	Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 769-77	15.1	38
45	Lumen enlargement of the coronary segments located distal to chronic total occlusions successfully treated with drug-eluting stents at follow-up. <i>EuroIntervention</i> , <b>2014</b> , 9, 1181-8	3.1	27
44	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 81, 42-9	2.7	12
43	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 14-7	5.1	11
42	Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 155-64	5.1	21
41	Early anticoagulation may improve preprocedural patency of the infarct-related artery in primary percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2013</b> , 66, 148-50	0.7	2
40	Platelet function and genetic testing. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, S21-31	15.1	23
39	Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 182-4	5	8
38	Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 119-26	4.9	5
37	Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. <i>American Journal of Cardiovascular Drugs</i> , <b>2013</b> , 13, 233-50	4	35
36	Multislice CT for assessing in-stent dimensions after left main coronary artery stenting: a comparison with three dimensional intravascular ultrasound. <i>Heart</i> , <b>2013</b> , 99, 1106-12	5.1	10
35	MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration. <i>Journal of Interventional Cardiology</i> , <b>2013</b> , 26, 1-7	1.8	8
34	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1223-31	7	12
33	Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 110-7	7	17
32	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2012</b> , 65, 105-106	0.7	1
31	Long-term Follow-up After Percutaneous Treatment of the Unprotected Left Main Stenosis in High Risk Patients Not Suitable for Bypass Surgery. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2012</b> , 65, 530-537	0.7	
30	Impact on delay times and characteristics of patients undergoing primary percutaneous coronary intervention in the southern metropolitan area of Barcelona after implementation of the infarction code program. <i>Revista Espanola De Cardiologia</i> , <b>2012</b> , 65, 911-8	1.5	35

29	New directions in antiplatelet therapy. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 433-45	6	52
28	Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1681-7	15.1	16
27	Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. <i>JACC: Cardiovascular Interventions</i> , <b>2012</b> , 5, 293-300	5	38
26	Effects of pioglitazone on platelet P2Y <sub>12</sub> -mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 930-6	7	13
25	Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5273-93	3.3	10
24	Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 30-9	15.1	44
23	Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1396-8	15.1	8
22	Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 905-12	5	16
21	Functional profile of the platelet P2Y <sub>12</sub> receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 730-2	7	34
20	Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 67-74	7	33
19	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 253-62	7	32
18	Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 273-9	6	31
17	Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 180-7	6	151
16	Diabetes and antiplatelet therapy in acute coronary syndrome. <i>Circulation</i> , <b>2011</b> , 123, 798-813	16.7	229
15	Platelet function testing and risk of bleeding complications. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 1128-35	7	79
14	Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. <i>Circulation: Cardiovascular Interventions</i> , <b>2010</b> , 3, 436-41	6	47
13	Platelet abnormalities in diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , <b>2010</b> , 7, 251-9	3.3	138
12	Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , <b>2010</b> , 7, 274-88	3.3	5

11	Update on the clinical development of cangrelor. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 1069-73	2.7	19
10	Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1139-46	15.1	169
9	Platelet adenosine diphosphate P2Y <sub>12</sub> receptor antagonism: benefits and limitations of current treatment strategies and future directions. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2010</b> , 63, 60-76	0.7	17
8	Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. <i>International Journal of Cardiology</i> , <b>2010</b> , 145, 235-237	3.2	19
7	Inhibici3n del receptor plaquetario P2Y <sub>12</sub> de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terap3uticas actuales y perspectivas futuras. <i>Revista Espanola De Cardiologia</i> , <b>2010</b> , 63, 60-76	1.5	58
6	Impacto del tipo de hospital en el tratamiento y evoluci3n de los pacientes con s3ndrome coronario agudo sin elevaci3n del ST. <i>Revista Espanola De Cardiologia</i> , <b>2010</b> , 63, 390-399	1.5	29
5	Mechanism of action and clinical development of platelet thrombin receptor antagonists. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 1191-200	2.5	18
4	Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes. <i>Trends in Cardiovascular Medicine</i> , <b>2010</b> , 20, 211-7	6.9	2
3	Clopidogrel response variability: current status and future directions. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 7-14	7	91
2	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , <b>2009</b> , 7, 361-9	2.5	11
1	Cangrelor: a review on its mechanism of action and clinical development. <i>Expert Review of Cardiovascular Therapy</i> , <b>2009</b> , 7, 1195-201	2.5	71